SCHEMBL6862774

SCHEMBL6862774

CNC(=O)c1ccc(N2CCN(C)CC2)cc1-c1ccccc1C

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.55
CSF1R P07333 2/20 0.54
SIRT6 Q8N6T7 1/20 0.44
RAB9A P51151 7/20 0.44
NPC1 O15118 6/20 0.44
KMT2A Q03164 2/20 0.44
TSHR P16473 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HTR6 P50406 2/20 0.43
HTR3A P46098 1/20 0.43
MAPK14 Q16539 1/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
HTR2A P28223 1/20 0.42
PDK2 Q15119 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6868712 0.86 TACR1 (0.58) TACR1CSF1RRAB9ANPC1KMT2A
SCHEMBL2913153 0.85 TACR1 (0.57) TACR1CSF1RKMT2AHTR6HTR3A
SCHEMBL905364 0.80 TACR1 (0.57) TACR1CSF1RRAB9AKMT2AHTR3A
SCHEMBL6868721 0.77 RAB9A (0.63) SIRT6RAB9ANPC1KMT2ASMN1; SMN2
SCHEMBL2913155 0.75 MAPT (0.56) TACR1CSF1RSIRT6RAB9ANPC1
SCHEMBL1558664 0.74 MAPT (0.55) SIRT6RAB9ANPC1KMT2AHTR6
SCHEMBL29971293 0.73 GAA (0.53) KMT2ASMN1; SMN2MAPK1PDK2
SCHEMBL2908099 0.72 SIRT6 (0.60) SIRT6HTR6MAPTMAPK1
SCHEMBL6869271 0.72 L3MBTL1 (0.50) TACR1SIRT6RAB9ANPC1HTR6
Toluic Acid SCHEMBL28119604 0.72 HTR3A (0.47) TACR1RAB9ANPC1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1171419-B1 BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR HOFFMANN LA ROCHE (CH) 2004-12-29 EP disclosed
US-6552088-B2 2'-methyl-biphenyl-2-carboxylic acid-(3,5-bis-trifluoromethyl-benzyl)-methyl-amide, for example; treating disease related to neurokinin 1 receptor HOFFMANN-LA ROCHE INC. 2003-04-22 US disclosed
US-20020040060-A1 Biphenyl derivatives BOS MICHAEL (CA) 2002-04-04 US disclosed
EP-1171419-A1 BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2002-01-16 EP disclosed
US-6291465-B1 Biphenyl derivatives HOFFMANN-LA ROCHE INC. 2001-09-18 US disclosed
WO-2000053572-A1 BIPHENYL DERIVATIVES AS ANTAGONISTS OF THE NEUROKININE-1 RECEPTOR F. HOFFMANN-LA ROCHE AG (CH) 2000-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040060-A1 Biphenyl derivatives NR1H4, NR1H2, NR1H3 TACR1 16/4885CSF1R 554/4885SIRT6 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.